Skip to main content
Cost-effectiveness of pediatric leukemia CAR T-cell therapy studied

Researchers estimated that 40% of children with B-cell acute lymphoblastic leukemia who received the chimeric antigen receptor T-cell therapy Kymriah, or tisagenlecleucel, would survive after five years, compared with only 10.8% of those who were given clofarabine. The findings in JAMA Pediatrics also showed that tisagenlecleucel had a nearly $46,000 difference per quality-adjusted life year gained, compared with clofarabine, indicating its cost-effectiveness in treating pediatric ALL.

Full Story: